HQL Company Profile and Key Details

NYSE : HQL

Tekla Life Sciences Investors

$17.15

-0.51-2.89%

Open: 10:53 AM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Tekla Life Sciences Investors (HQL) stock declined over -2.89%, trading at $17.15 on NYSE, down from the previous close of $17.66. The stock opened at $17.10, fluctuating between $17.03 and $17.18 in the recent session.

Stock Snapshot

17.66

Prev. Close

521.5M

Market Cap

17.03

Day Low

6.15

P/E Ratio

2.79

EPS (TTM)

Cash Flow per Share

17.1

Open

30.41M

Number of Shares

17.18

Day High

93.31%

Free Float in %

Book Value

46.79K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 20, 2026	17.47	17.68	17.47	17.66	179.04K
May 19, 2026	17.64	17.64	17.30	17.41	130.34K
May 18, 2026	17.85	17.89	17.55	17.67	125.55K
May 15, 2026	18.19	18.23	17.77	17.78	83.48K
May 14, 2026	18.25	18.33	18.12	18.20	71.32K
May 13, 2026	18.14	18.22	18.09	18.19	64.54K
May 12, 2026	18.10	18.20	18.02	18.09	128.25K
May 11, 2026	18.22	18.46	18.10	18.11	115.55K
May 08, 2026	18.03	18.19	17.95	18.19	96.43K
May 07, 2026	18.25	18.27	17.75	17.95	127.88K
May 06, 2026	17.96	18.28	17.94	18.22	131.97K
May 05, 2026	17.89	18.00	17.75	17.90	65.5K
May 04, 2026	17.55	17.84	17.55	17.72	82.94K
Apr 30, 2026	17.46	17.69	17.46	17.50	217.99K
Apr 29, 2026	17.55	17.63	17.29	17.40	60.45K
Apr 28, 2026	17.53	17.79	17.44	17.53	85.06K
Apr 27, 2026	17.37	17.68	17.37	17.56	82.64K
Apr 23, 2026	17.70	17.80	17.36	17.41	56.31K
Apr 22, 2026	17.92	17.94	17.57	17.68	53.82K
Apr 21, 2026	18.01	18.10	17.67	17.90	75.79K

Contact Details

Philadelphia, MA 02110

United States

https://www.teklacap.com/hql.html 617 772 8500

About Company

Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.

Stock Peers

BLK

15.27+1.47%

BlackRock, Inc.$1,051.57 AMP

-6.49-1.40%

Ameriprise Financial, Inc.$457.27 AMG

6.44+2.18%

Affiliated Managers Group, Inc.$301.34 VCX

8.95+3.88%

Fundrise Growth Tech Fund, LLC$239.76 STT

3.19+2.11%

State Street Corporation$154.07 BK

0.84+0.62%

The Bank of New York Mellon Corporation$137.16 SII

2.54+2.04%

Sprott Inc.$127.17 ARES

1+0.83%

Ares Management Corporation$122.11 BX

2.57+2.25%

Blackstone Inc.$116.83 SHOC

4.08+4.00%

Strive U.S. Semiconductor ETF$106.11

Company Overview

Tekla Life Sciences Investors (NYSE:HQL) closed at $17.08 USD, losing -$0.58 (-3.28%) from the previous close of $17.66. The stock is currently mid-range between its 52-week high and low $12.12 and $18.46. With a market capitalization of about $519.37 million, Tekla Life Sciences Investors is classified as a small-cap and shows lower-than-market volatility (beta ~0.74). Key stats such as the average daily volume over the past year has been around 107.73 thousand shares, volume is running light vs its 52-week average. Headquartered in Philadelphia, MA, Tekla Life Sciences Investors operates in the Financial Services sector and the Asset Management industry. Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe.

Technical Performance

HQL has shown mixed momentum, losing -0.6% over the past week and 0.91% over the past quarter, though year-to-date performance is down -0.77%. Short-term trend indicators are bearishly aligned (SMA20 -1.96%, SMA50 -1.79%, SMA200 10.13%). The stock’s 14-day RSI is 42.33 (neutral), while the ATR of 0.33 points to moderate volatility. The stock remains hovering near 52-week lows, trading -6.52% below its high and over 57.72% above its low. Average 10-day trading volume of 112.26 thousand shares is in line with the 3-month average of 109.69 thousand, indicating normal recent market interest.

Valuation Metrics

Tekla Life Sciences Investors trades at a P/E ratio of 5.96, slightly below the S&P 500 average, with a price-to-sales ratio of 18.0 and a price-to-book ratio of 0.99 suggesting the stock is closer to book value. The P/FCF stands at -231.44, also below market averages.

Dividend & Fair Value

Tekla Life Sciences Investors last paid a dividend of 1.91 per share, this equals a trailing yield of roughly 8.57%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.69. This means the shares are trading below this model’s fair value.

Financial & Profitability Overview

Over the trailing twelve months, Tekla Life Sciences Investors generated $86.39M in revenue, or $2.99 per share. Gross margin was 100.00%, operating margin 99.08%, and net profit margin 99.08%. Returns are healthy, with ROA at 16.61% and ROE at 16.66%.
On valuation metrics, Tekla Life Sciences Investors trades at a P/E of 5.96, P/S of 18.00 and P/B of 0.99. The current ratio is 1.74 and quick ratio is 1.74. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -39.01 days , indicating it collects cash faster than it pays suppliers.

Quarterly Financial Highlights

For the quarter ended Sep 30, 2025, Tekla Life Sciences Investors posted revenue of $86.39M, down slightly from $86.69M in the prior quarter. Gross profit was $86.39M (margin 100.00%). Operating income was $85.59M (margin 99.1%). Net income was$85.59M (EPS $2.96).
The company ended the quarter with $75.54K in cash and short-term investments, a total debt of $0.00, and net debt of - $75.54K. Total assets were $515.38M, with equity of $513.66M.

Price Forecast & Outlook

Our AI price prediction model suggests that Tekla Life Sciences Investors stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.13%, with price expected at $17.86 by June 03, 2026, within a range of $17.58 to $18.17 3-Month Outlook: Projected rise of 24.07%, reaching $21.91 by August 18, 2026, with a range of $21.26 to $22.65. 1-Year Outlook: Projected gain of 6.34%, with price at $18.78 by May 20, 2027, within a range of $18.34 to $19.35.

Key Takeaways

Tekla Life Sciences Investors (NYSE:HQL) shares are flat -0.77% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Tekla Life Sciences Investors trading at a premium to the broader market with a P/E of 5.96. Our AI forecast model points to short-term strength (1.13% over two weeks), a medium-term rise (24.07% over three months), and a longer-term gain (6.34% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Tekla Life Sciences Investors (HQL) stock price?

Tekla Life Sciences Investors (NYSE: HQL) stock price is $17.15 in the last trading session. During the trading session, HQL stock reached the peak price of $17.18 while $17.03 was the lowest point it dropped to. The percentage change in HQL stock occurred in the recent session was -2.89% while the dollar amount for the price change in HQL stock was - $0.51.

HQL's industry and sector of operation?

The NYSE listed HQL is part of Asset Management industry that operates in the broader Financial Services sector. Tekla Life Sciences Investors designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of HQL?

No Data

How HQL did perform over past 52-week?

HQL's closing price is 45.71% higher than its 52-week low of $12.12 where as its distance from 52-week high of $18.46 is -4.33%.

How many employees does HQL have?

Number of HQL employees currently stands at 0.

Link for HQL official website?

Official Website of HQL is: https://www.teklacap.com/hql.html

How do I contact HQL?

HQL could be contacted at phone 617 772 8500 and can also be accessed through its website. HQL operates from 100 Federal Street, Philadelphia, MA 02110, United States.

How many shares of HQL are traded daily?

HQL stock volume for the day was 46.79K shares. The average number of HQL shares traded daily for last 3 months was 107.73K.

What is the market cap of HQL currently?

The market value of HQL currently stands at $521.50M with its latest stock price at $17.15 and 30.41M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	0
Beta	0.75
Sales or Revenue	$86.39M
5Y Sales Change%	8.381%
Fiscal Year Ends	September
Sector	Financial Services
Industry	Asset Management

HQL Company Profile and Key Details

Tekla Life Sciences Investors

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Price Forecast & Outlook

Key Takeaways

Financial & Profitability Overview

Quarterly Financial Highlights